DE69215999D1 - Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs - Google Patents

Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs

Info

Publication number
DE69215999D1
DE69215999D1 DE69215999T DE69215999T DE69215999D1 DE 69215999 D1 DE69215999 D1 DE 69215999D1 DE 69215999 T DE69215999 T DE 69215999T DE 69215999 T DE69215999 T DE 69215999T DE 69215999 D1 DE69215999 D1 DE 69215999D1
Authority
DE
Germany
Prior art keywords
treatment
cancer
therapeutic agents
drug resistance
dihydrocinchonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69215999T
Other languages
English (en)
Other versions
DE69215999T2 (de
Inventor
Bruno Chauffert
Philippe Genne
Gilles Gutierrez
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH57691A external-priority patent/CH682050A5/fr
Priority claimed from CH352291A external-priority patent/CH683238A5/fr
Application filed by Debiopharm SA, Patrinove, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Debiopharm SA
Application granted granted Critical
Publication of DE69215999D1 publication Critical patent/DE69215999D1/de
Publication of DE69215999T2 publication Critical patent/DE69215999T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69215999T 1991-02-25 1992-02-24 Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs Expired - Fee Related DE69215999T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH57691A CH682050A5 (en) 1991-02-25 1991-02-25 Use of cinchonine, di:hydro:cinchonine or hydro:quinidine
CH352291A CH683238A5 (fr) 1991-12-02 1991-12-02 Hydroquinidine, comme agent thérapeutique et son utilisation dans une composition pharmaceutique.
PCT/EP1992/000408 WO1992014467A1 (fr) 1991-02-25 1992-02-24 Agents therapeutiques pour le traitement de la resistance multidrogue de cancers

Publications (2)

Publication Number Publication Date
DE69215999D1 true DE69215999D1 (de) 1997-01-30
DE69215999T2 DE69215999T2 (de) 1997-07-03

Family

ID=25685005

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69215999T Expired - Fee Related DE69215999T2 (de) 1991-02-25 1992-02-24 Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs

Country Status (9)

Country Link
US (1) US5635515A (de)
EP (1) EP0526608B1 (de)
JP (1) JPH06505991A (de)
AT (1) ATE146361T1 (de)
AU (1) AU649787B2 (de)
CA (1) CA2081343C (de)
DE (1) DE69215999T2 (de)
ES (1) ES2097905T3 (de)
WO (1) WO1992014467A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5866699A (en) * 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
FR2764509A1 (fr) 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
EP2289549A3 (de) 1999-10-01 2011-06-15 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
AU2002363523A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2008105872A1 (en) * 2007-02-28 2008-09-04 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
WO2014145386A2 (en) * 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel allosteric inhibitors of thymidylate synthase
EP3104859A1 (de) * 2014-02-12 2016-12-21 Adam Mickiewicz University Verwendung von chinarindenalkaloid-derivate als zytotoxische verbindungen
CN105796558A (zh) * 2014-12-31 2016-07-27 天津大学 辛可宁在制备抗肿瘤药物的用途
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
US11066421B1 (en) 2021-02-09 2021-07-20 Ares Pharmaceuticals, LLC Synthetic cinchona alkaloids against cancer
US11649232B2 (en) 2021-05-10 2023-05-16 Ares Pharmaceuticals, LLC Synthetic dimeric cinchona alkaloids against cancer
WO2023177376A2 (en) * 2022-03-17 2023-09-21 Mugla Sitki Kocman Universitesi Idari Mali Isler Baskanligi The use of the molecule hydroquinidine in the treatment of brain tumors
WO2023230702A1 (en) * 2022-06-03 2023-12-07 University Of Manitoba Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen

Also Published As

Publication number Publication date
US5635515A (en) 1997-06-03
DE69215999T2 (de) 1997-07-03
CA2081343C (fr) 2003-09-16
CA2081343A1 (fr) 1992-08-26
EP0526608B1 (de) 1996-12-18
EP0526608A1 (de) 1993-02-10
JPH06505991A (ja) 1994-07-07
AU649787B2 (en) 1994-06-02
ES2097905T3 (es) 1997-04-16
ATE146361T1 (de) 1997-01-15
AU1206292A (en) 1992-09-15
WO1992014467A1 (fr) 1992-09-03

Similar Documents

Publication Publication Date Title
ATE146361T1 (de) Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
DE60143857D1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
ATE495793T1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
JP2006500346A5 (de)
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
TR200002969T2 (tr) Farmasötik bileşim.
IL165086A (en) Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
BR0008305A (pt) Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica
JP2005513147A5 (de)
ATE277622T1 (de) Arzneimittel enthaltend xenogene oligo- oder/und polyribonukleotide
WO2023001283A9 (zh) 用于治疗胃癌和/或食管胃结合部癌的联用药物
ITMI991931A0 (it) Combinazione di differenti composizioni farmaceutiche per il trattamen to del carcinoma mammario e relativo metodo di somministrazione
UA83988C2 (ru) Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee